Zhiyong Wang

Founder & Chief Scientific Officer Venquis Therapeutics

Seminars

Wednesday 17th September 2025
Small Molecule Direct Degraders for Cancer Driver Proteins
11:30 am
  • PI3Kalpha mutant and isoform specific degraders
  • Positive selection screening strategy for KRAS G12D degraders
  • Development of novel KRAS degraders
Wednesday 17th September 2025
Small Molecule Direct Degraders for Cancer Driver Proteins
2:00 pm
  • PI3Kalpha mutant and isoform specific degraders
  • Positive selection screening strategy for KRAS G12D degraders
  • Development of novel KRAS degraders
Zhiyong Wang, CSO, Venquis Therapeutics